FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
What happened
FDA inspected Rohto-Mentholatum (Vietnam) Co., Ltd. from April 6 to 14, 2026, and found systemic falsification of environmental, personnel, and cleaning records; actual plate readings during the inspection showed microbial growth, including about 25 excursions in critical sterile areas (ISO 5). FDA also reviewed the website and Instagram in August 2026 and found seven ROHTO Cooling Eye Drops products to be unapproved new drugs and misbranded. FDA cited inadequate investigations of visible particles in two released sterile eye-drop batches and consumer complaints of leakage, burning, and foreign matter.
What FDA found
The company falsified environmental, personnel, and cleaning records, including by submitting unexposed plates and documenting cleaning that was not performed.
21 CFR 211.194(a) and 21 CFR 211.67(a)The company did not properly control aseptic (sterile) processing, with operators mishandling open sterile bottles and undocumented interventions in the ISO 5 critical area.
21 CFR 211.113(b) and 21 CFR 211.63The company did not adequately investigate visible particles in two released sterile eye-drop batches or consumer complaints of leakage, burning, and foreign matter.
21 CFR 211.192Seven ROHTO Cooling Eye Drops products are unapproved new drugs because they lack an FDA-approved application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The same products are misbranded under the Federal Food, Drug, and Cosmetic Act.
FD&C Act sections 502(a) and 502(ee), 21 U.S.C. 352(a) and 352(ee)The company's drugs are adulterated because its manufacturing methods did not conform to CGMP.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells Rohto to promptly correct the violations and provide independent assessments, corrective action and preventive action (CAPA) plans, and remediation plans for its laboratory, documentation, aseptic, cleaning, visual inspection, and quality systems. The letter does not state a specific response deadline.
Who should pay attention
- U.S. brands and distributors selling Rohto eye drops
- sterile ophthalmic drug manufacturers
- quality teams that rely on environmental monitoring records
This is a summary. Read the original letter on fda.gov.